K Van der Heiden, S Cuhlmann, LA Luong… - Clinical …, 2010 - portlandpress.com
Cardiovascular pathologies are still the primary cause of death worldwide. The molecular mechanisms behind these pathologies have not been fully elucidated. Unravelling them will …
FC Barone, RF White, PA Spera, J Ellison, RW Currie… - Stroke, 1998 - Am Heart Assoc
Background and Purpose—A short duration of ischemia (ie, ischemic preconditioning [PC]) can provide significant brain protection to subsequent ischemic events (ie, ischemic …
GJ Grover, KD Garlid - Journal of molecular and cellular cardiology, 2000 - Elsevier
GJ Grover and KA Garlid. ATP-Sensitive Potassium Channels: A Review of their Cardioprotective Pharmacology. Journal of Molecular and Cellular Cardiology (2000) 32 …
G Solaini, DA Harris - Biochemical Journal, 2005 - portlandpress.com
Heart tissue is remarkably sensitive to oxygen deprivation. Although heart cells, like those of most tissues, rapidly adapt to anoxic conditions, relatively short periods of ischaemia and …
KJ Loaeza-Reyes, E Zenteno… - Frontiers in molecular …, 2021 - frontiersin.org
The cardiovascular system is a complex and well-organized system in which glycosylation plays a vital role. The heart and vascular wall cells are constituted by an array of specific …
AM Shah, PA MacCarthy - Pharmacology & therapeutics, 2000 - Elsevier
Complex paracrine interactions exist between endothelial cells and cardiac myocytes in the heart. Cardiac endothelial cells release (or metabolize) several diffusible agents (eg, nitric …
R Schulz, MV Cohen, M Behrends… - Cardiovascular …, 2001 - academic.oup.com
1. Ischemic preconditioning and its endpoints morphological protection, while on the other hand caution should be used when extrapolating findings from short-Brief episodes of …
HT Lee, CW Emala - American Journal of Physiology-Renal …, 2000 - journals.physiology.org
Renal ischemia and reperfusion during aortic and renal transplant surgery result in ischemic- reperfusion injury. Ischemic preconditioning and adenosine infusion before ischemia protect …
The phosphodiesterase type-5 (PDE5) inhibitor, sildenafil, is the first drug developed for treatment of erectile dysfunction in patients. Experimental data in animals show that …